#ESMO26 🧬 DEWI | 第 II 期
👥 43 例 | 局限性 dMMR/MSI-H GEA
💊 Dostarlimab → 若达完全缓解则观察等待
🎯 1 年完全缓解且器官保留：67.4%（29/43）
✅ 29 例观察等待患者中无复发或死亡
🏥 手术：14/43（32.5%）
⚠️ 随访：14.9 个月
💡 极具前景的器官保留策略！
@OncoAlert @OncobitesTv
332 浏览 · 2 赞 · 4 转发 · 1 回复
Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study
https://esmocongress.esmo.org- Muzamil Arshad, MD/PhD@MuzamilArshad18
@DraMartinezLago @OncoAlert @myESMO @GrupoTTD Among non cCR could addition of RT prevent surgery in 1/3 who needed surgery?! 🤔 But also Niche studies with dual checkpoint had near 100% responses as I recall .. exciting to see various combo options for organ preservation … for other 95+% cases love IO+ ☢️ trials
来源：Nieves Martinez Lago MD PhD · x.com